Eugenio Fardella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eugenio Fardella has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Adam D. Cohen
Abramson Cancer Center and University of Pennsylvania, Philadelphia, USA
2 shared publications Adam J. Waxman
2 shared publications- Annalisa Chiappella
Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
2 shared publications - Cristiana Carniti
Hematology Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy
2 shared publications - Dan T. Vogl
Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
2 shared publications David L. Porter
2 shared publications
Latest Publications
- Open Access
- 16 July 2025
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 1 (2)
Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma
- 16 July 2025
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 1 (2)
Open AccessAccess and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma
- Open Access
- 15 April 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (8) , 1968-1980
Monocytes in leukapheresis products affect the outcome of CD19–targeted CAR T-cell therapy in patients with lymphoma
CD19–directed chimeric antigen receptor (CAR) T cells can induce durable remissions in relapsed/refractory large B-cell lymphomas (R/R LBCLs), but 60% of patients do not respond or relapse. Biological mechanisms explaining lack of response are emerging, but they are largely unsuccessful in predicting disease response at the patient level. Additionally, to maximize the cost-effectiveness of CAR T-cell therapy, biomarkers able to predict response and survival before CAR T-cell manufacturing would be desirable. We performed transcriptomic and functional evaluations of leukapheresis products in 95 patients with R/R LBCL enrolled in a prospective observational study, to identify correlates of response and survival to tisagenlecleucel and axicabtagene ciloleucel. A signature composed of 4 myeloid genes expressed by T cells isolated from leukapheresis products is able to identify patients with a very short progression-free survival (PFS), highlighting the impact of monocytes in CAR T-cell therapy response. Accordingly, response and PFS were also negatively influenced by high circulating absolute monocyte counts at the time of leukapheresis. The combined evaluation of peripheral blood monocytes at the time of leukapheresis and the 4-gene signature represents a novel tool to identify patients with R/R LBCL at very high risk of progression after CAR T-cell therapy and could be used to plan trials evaluating CAR T cells vs other novel treatments or allogeneic CAR T cells. However, it also highlights the need to incorporate monocyte depletion strategies for better CAR T production.
- 15 April 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (8) , 1968-1980
Open AccessMonocytes in leukapheresis products affect the outcome of CD19–targeted CAR T-cell therapy in patients with lymphoma
CD19–directed chimeric antigen receptor (CAR) T cells can induce durable remissions in relapsed/refractory large B-cell lymphomas (R/R LBCLs), but 60% of patients do not respond or relapse. Biological mechanisms explaining lack of response are emerging, but they are largely unsuccessful in predicting disease response at the patient level. Additionally, to maximize the cost-effectiveness of CAR T-cell therapy, biomarkers able to predict response and survival before CAR T-cell manufacturing would be desirable. We performed transcriptomic and functional evaluations of leukapheresis products in 95 patients with R/R LBCL enrolled in a prospective observational study, to identify correlates of response and survival to tisagenlecleucel and axicabtagene ciloleucel. A signature composed of 4 myeloid genes expressed by T cells isolated from leukapheresis products is able to identify patients with a very short progression-free survival (PFS), highlighting the impact of monocytes in CAR T-cell therapy response. Accordingly, response and PFS were also negatively influenced by high circulating absolute monocyte counts at the time of leukapheresis. The combined evaluation of peripheral blood monocytes at the time of leukapheresis and the 4-gene signature represents a novel tool to identify patients with R/R LBCL at very high risk of progression after CAR T-cell therapy and could be used to plan trials evaluating CAR T cells vs other novel treatments or allogeneic CAR T cells. However, it also highlights the need to incorporate monocyte depletion strategies for better CAR T production.
- Top Cited Papers
- 24 January 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (4) , 984-989
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
We report a T-cell lymphoma (TCL) occurring three months after anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy for non-Hodgkin B-cell lymphoma. The TCL was diagnosed from a thoracic lymph node upon surgery for lung cancer. The TCL exhibited CD8+ cytotoxic phenotype and a JAK3 variant, while the CAR transgene was very low. The T-cell clone was identified at low levels in the blood before CART infusion and in the lung cancer. To assess the overall risk of secondary primary malignancy (SPM) after commercial CART (CD19, BCMA), we analyzed 449 patients treated at the University of Pennsylvania. At a median follow-up of 10.3 months, 16 patients (3.6%) had SPM. Median onset time was 26.4 and 9.7 months for solid and hematological malignancies, respectively. The projected 5-year cumulative incidence is 15.2% for solid and 2.3% for hematological malignancies. Overall, one case of TCL was observed, suggesting a low risk of TCL post-CART.
- 24 January 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (4) , 984-989
Top Cited PapersT cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
We report a T-cell lymphoma (TCL) occurring three months after anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy for non-Hodgkin B-cell lymphoma. The TCL was diagnosed from a thoracic lymph node upon surgery for lung cancer. The TCL exhibited CD8+ cytotoxic phenotype and a JAK3 variant, while the CAR transgene was very low. The T-cell clone was identified at low levels in the blood before CART infusion and in the lung cancer. To assess the overall risk of secondary primary malignancy (SPM) after commercial CART (CD19, BCMA), we analyzed 449 patients treated at the University of Pennsylvania. At a median follow-up of 10.3 months, 16 patients (3.6%) had SPM. Median onset time was 26.4 and 9.7 months for solid and hematological malignancies, respectively. The projected 5-year cumulative incidence is 15.2% for solid and 2.3% for hematological malignancies. Overall, one case of TCL was observed, suggesting a low risk of TCL post-CART.
- Open Access
- 4 January 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 1752-1756
Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas
Summary: Peripheral T‐cell lymphomas (PTCLs) have a poor prognosis and, to date, there are no reliable predictive biomarkers of response. In this work we explored the prognostic impact of cell‐free DNA (cfDNA) concentration in 75 newly diagnosed patients enrolled in a prospective multicenter study. Pre‐treatment cfDNA was strongly associated with clinical risk factors and was identified as a superior predictor for shorter progression‐free survival in multivariable analysis, outweighing canonical risk parameters. Furthermore, we identified a cfDNA value above which survival worsens. In conclusion, pre‐treatment cfDNA concentration represents an easily usable predictive biomarker that is highly associated with survival of PTCL patients.
- 4 January 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 1752-1756
Open AccessPrognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas
Summary: Peripheral T‐cell lymphomas (PTCLs) have a poor prognosis and, to date, there are no reliable predictive biomarkers of response. In this work we explored the prognostic impact of cell‐free DNA (cfDNA) concentration in 75 newly diagnosed patients enrolled in a prospective multicenter study. Pre‐treatment cfDNA was strongly associated with clinical risk factors and was identified as a superior predictor for shorter progression‐free survival in multivariable analysis, outweighing canonical risk parameters. Furthermore, we identified a cfDNA value above which survival worsens. In conclusion, pre‐treatment cfDNA concentration represents an easily usable predictive biomarker that is highly associated with survival of PTCL patients.